| |
|
| |
|
 |
Navigating
the Choices for Diabetes Prevention |
| |
In this issue of the Journal, the investigators
of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study report the
results of their international trial (NEJM) |
| |
|
|
ACCORD
and Risk-Factor Control in Type 2 Diabetes |
| |
The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study was one of the landmark trials to evaluate
the overall effects of drug intervention in patients with type
2 diabetes (NEJM) |
| |
|
|
ACCORD:
Intensive BP treatment failed to reduce CV risk in patients with
diabetes |
| |
Intensive blood pressure treatment did not reduce
the overall risk for cardiovascular events in patients with type
2 diabetes, elevated BP and high CV risk when compared with more
conventional therapy, according to new data from the ACCORD Blood
Pressure trial (Cardiology Today) |
| |
|
|
Commencement
of the Saxagliptin Assessment of Vascular Outcomes |
| |
Bristol-Myers Squibb and AstraZeneca Announce
the Commencement of the Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients with Diabetes Mellitus Trial (PharmaLive) |
| |
|
|
Generic
Drug for Type 2 Diabetes Passes Next Clinical Hurdle |
| |
Salsalate, an anti-inflammatory agent, shows
encouraging results in preliminary trial led by (Joslin Diabetes
Center) |
| |
|
|
FDA
turns down once-weekly Byetta |
| |
Amylin, Eli Lilly and Alkermes will have to
wait a bit longer before they can start selling a once-weekly version
of its diabetes blockbuster Byetta as regulators in the USA want
clarification on the labelling (PharmaTimes) |
| |
|
|
Endothelial
Dysfunction: the Common Consequence in Diabetes and Hypertension |
| |
Endothelial dysfunction plays a key role in
the initiation of cellular events evolving into the development
of vascular complications in diabetes and hypertension - Abstract
(Journal of Cardiovascular Pharmacology) |
| |
|
|
Testosterone
concentrations in diabetic and non-diabetic obese men |
| |
40% of obese non-diabetic and 50% of obese diabetic
men above the age of 45 years have subnormal FT concentrations
(Diabetes Care) |
| |
|
|
IDF
appoints Special Ambassador for the Rights of People with Diabetes |
| |
The International Diabetes Federation (IDF)
is pleased to announce the appointment of Dr Wim Wientjens as IDF Special Ambassador for the Rights of People with Diabetes (IDF) |
| |
|
|
Primary
Care Diabetes |
| |
April edition (PCD) |
| |
|
